Alector (NASDAQ:ALEC) Trading Up 6.6%

Alector Inc (NASDAQ:ALEC)’s share price was up 6.6% during mid-day trading on Tuesday . The stock traded as high as $16.10 and last traded at $16.00, approximately 328,038 shares were traded during trading. An increase of 14% from the average daily volume of 288,251 shares. The stock had previously closed at $15.01.

Several research analysts have issued reports on ALEC shares. Zacks Investment Research lowered shares of Alector from a “hold” rating to a “sell” rating in a report on Tuesday. Cowen restated a “buy” rating on shares of Alector in a report on Wednesday, July 17th. Finally, ValuEngine lowered shares of Alector from a “buy” rating to a “hold” rating in a report on Friday, September 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $26.67.

The firm’s 50 day moving average price is $16.30 and its two-hundred day moving average price is $18.63. The company has a market cap of $990.15 million and a P/E ratio of -3.46. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.18 and a current ratio of 6.18.

Alector (NASDAQ:ALEC) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.03). The firm had revenue of $6.92 million for the quarter. As a group, analysts forecast that Alector Inc will post -1.4 EPS for the current fiscal year.

In other news, major shareholder Orbimed Advisors Llc sold 650,000 shares of Alector stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $17.90, for a total value of $11,635,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Robert Paul sold 2,000 shares of Alector stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $16.00, for a total transaction of $32,000.00. The disclosure for this sale can be found here. Insiders sold a total of 686,000 shares of company stock valued at $12,229,800 in the last quarter. 34.40% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in ALEC. Virtus ETF Advisers LLC acquired a new stake in Alector in the 2nd quarter valued at $251,000. Wells Fargo & Company MN grew its position in Alector by 89.2% in the 2nd quarter. Wells Fargo & Company MN now owns 13,650 shares of the company’s stock valued at $259,000 after purchasing an additional 6,434 shares during the period. Bank of New York Mellon Corp grew its position in Alector by 150.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,156 shares of the company’s stock valued at $611,000 after purchasing an additional 19,302 shares during the period. Citadel Advisors LLC acquired a new stake in Alector in the 2nd quarter valued at $798,000. Finally, Charles Schwab Investment Management Inc. grew its position in Alector by 20.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 56,744 shares of the company’s stock valued at $1,079,000 after purchasing an additional 9,771 shares during the period. Institutional investors own 40.52% of the company’s stock.

About Alector (NASDAQ:ALEC)

Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.

Read More: Backdoor Roth IRA Conversion and Strategy

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit